Toxic epidermal necrolysis induced by axitinib in a patient with advanced lung adenocarcinoma

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) inhibitors are crucial targeted therapies in oncology.
• Adverse skin reactions are common with EGFR inhibitor therapy.
• Severe cutaneous adverse reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), pose significant risks.

Purpose of the Study:

• To highlight the critical association between oral EGFR inhibitors and the risk of developing SJS/TEN.
• To emphasize the importance of recognizing widespread rash as a warning sign.

Main Methods:

• This is a summary of clinical observations and existing literature.
• Analysis of patient data and reported adverse events associated with EGFR inhibitor use.

Main Results:

• A sudden onset of widespread rash in patients on oral EGFR inhibitors is a significant indicator of potential SJS/TEN.
• Timely identification and management of this symptom can mitigate the severity of the reaction.

Conclusions:

• Patients receiving oral EGFR inhibitors require vigilant monitoring for dermatological changes.
• Prompt medical evaluation for widespread rash is essential to manage the risk of SJS/TEN effectively.